Seizert Capital Partners LLC Sells 321 Shares of QuidelOrtho Co. (NASDAQ:QDEL)

Seizert Capital Partners LLC trimmed its stake in shares of QuidelOrtho Co. (NASDAQ:QDEL) by 1.3% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 24,242 shares of the company’s stock after selling 321 shares during the quarter. Seizert Capital Partners LLC’s holdings in QuidelOrtho were worth $1,105,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of QuidelOrtho by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 4,879,143 shares of the company’s stock valued at $233,906,000 after acquiring an additional 37,733 shares during the period. Rubric Capital Management LP lifted its position in shares of QuidelOrtho by 51.9% during the 2nd quarter. Rubric Capital Management LP now owns 3,645,590 shares of the company’s stock worth $121,106,000 after buying an additional 1,245,590 shares during the last quarter. Maverick Capital Ltd. lifted its position in shares of QuidelOrtho by 27.5% during the 2nd quarter. Maverick Capital Ltd. now owns 1,728,913 shares of the company’s stock worth $57,434,000 after buying an additional 372,662 shares during the last quarter. Private Management Group Inc. lifted its position in shares of QuidelOrtho by 2.6% during the 3rd quarter. Private Management Group Inc. now owns 626,705 shares of the company’s stock worth $28,578,000 after buying an additional 16,084 shares during the last quarter. Finally, Van Lanschot Kempen Investment Management N.V. lifted its position in shares of QuidelOrtho by 9.8% during the 2nd quarter. Van Lanschot Kempen Investment Management N.V. now owns 593,157 shares of the company’s stock worth $19,705,000 after buying an additional 52,729 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price objective on shares of QuidelOrtho in a research report on Friday, August 16th. Craig Hallum upgraded QuidelOrtho from a “hold” rating to a “buy” rating and upped their price objective for the stock from $40.00 to $57.00 in a research report on Thursday, September 5th. Finally, UBS Group assumed coverage on QuidelOrtho in a research report on Thursday, September 19th. They set a “neutral” rating and a $50.00 price objective for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, QuidelOrtho currently has an average rating of “Hold” and an average price target of $58.83.

QuidelOrtho Price Performance

QuidelOrtho stock opened at $36.18 on Monday. The company has a current ratio of 1.38, a quick ratio of 0.81 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $2.43 billion, a PE ratio of -1.30 and a beta of 0.12. QuidelOrtho Co. has a 12 month low of $29.74 and a 12 month high of $75.86. The stock has a 50-day moving average price of $42.03 and a two-hundred day moving average price of $40.45.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Thursday, November 7th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.30 by $0.55. The firm had revenue of $727.00 million during the quarter, compared to the consensus estimate of $642.16 million. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. During the same period last year, the company earned $0.90 earnings per share. Analysts expect that QuidelOrtho Co. will post 1.72 EPS for the current year.

QuidelOrtho Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.